Pfizer Issues Voluntary Nationwide Recall For Twelve Lots Of Chantix Tablets Due To N-Nitroso Varenicline Content

T-Reuters2021-07-17

Pfizer Inc:Pfizer Issues A Voluntary Nationwide Recall For Twelve Lots Of Chantix® (Varenicline) Tablets Due To N-Nitroso Varenicline Content.Wholesalers, Distributors With Existing Inventory Of The Lots Should Stop Use & Distribution; Quarantine The Product Immediately.Pfizer-Recalling 2 Lots Of Chantix 0.5Mg, 2 Lots Of Chantix 1 Mg Tablets, 8 Lots Of Chantix Kit Of 0.5Mg/1 Mg Tablets Due To Presence Of Nitrosamine.Believes The Benefit/Risk Profile Of Chantix Remains Positive.To Date, Pfizer Has Not Received Any Reports Of Adverse Events That Have Been Related To This Recall.As Communicated By Fda, There Is No Immediate Risk To Patients Taking Chantix.Further Company Coverage:. ((Reuters.Briefs@Thomsonreuters.Com;)).

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

Leave a comment
125